University of GenevaSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Tag Archive for: financing
FIDA Biosystems ApSFida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discovery.
adobe stock photos - deemerwhaCologne-based Disco Pharmaceuticals GmbH has closed its seed financing at €36m. The company will use the proceeds to advance its surfaceome-mapping platform, developing bispecific ADCs and T-Cell Engagers for hard-to-treat cancers.
Tetraneuron SL - Álvaro GarcíaSpanish Tetraneuron secures financing to advance its E2F4DN-based Alzheimer’s gene therapy, restoring neuronal homeostasis and halting disease progression in Europe.
Cellular Origins LtdUK-bad Cellular Origins Ltd raised $40m to scale global CGT manufacturing with robotic automation, boosting access to cell therapies and enabling commercial growth.
Melt & Marble ABSwedish Melt&Marble AB has raised €7.3m to scale precision-fermented designer fats for sustainable, high-performance food and personal care ingredients.
EIB, Oscar RomanoThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support European biotechnology and digital health start-ups through seven to ten funding rounds. This marks the EIB’s first partnership with a corporate venture capital firm in Europe’s health sector under its TechEU programme.
freshidea / Adobe StockLyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets.
adobe.stock.photos - Yurii Kibalnik Dutch Avanzanite Biosciences NV has secured €32 m in a Series A financing round from MVM Partners to scale orphan drug commercialisation across Europe.
Medicxi VC specialist Medicxi has closed its oversubscribed €500m Fund V to support existing biopharmaceutical developers, and creating new companies across all development stages.